AMENDMENT TRANSMITTAL LETTER (Large Entity) Docket No. Applicant(s): Drewry et al. PR60418USW Application No. Filing Date Examiner Customer No. Group Art Unit Confirmation No. 10/566.040 1/26/06 J. Mabry 23347 1625 9316 Invention: CHEMICAL COMPOUNDS COMMISSIONER FOR PATENTS: Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below. CLAIMS AS AMENDED HIGHEST # NUMBER EXTRA CLAIMS REMAINING ADDITIONAL RATE AFTER AMENDMENT PREV. PAID FOR CLAIMS PRESENT FEE TOTAL CLAIMS 2 20 0 х \$50.00 \$0.00 INDEP CLAIMS 1 3 0 \$210.00 \$0.00 Multiple Dependent Claims (check if applicable) \$0.00 \$0.00 TOTAL ADDITIONAL FEE FOR THIS AMENDMENT No additional fee is required for amendment. Please charge Deposit Account No. in the amount of A check in the amount of to cover the filing fee is enclosed. Management The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392 Any additional filing fees required under 37 C.F.R. 1.16. Any patent application processing fees under 37 CFR 1.17. Payment by credit card. Form PTO-2038. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. 3/21/08 Signature John L. Lemanowicz, Reg. No. 37,380 Attorney for Applicants I hereby certify that this correspondence is being deposited with GlaxoSmithKline the United States Postal Service with sufficient postage as first Five Moore Drive, PO Box 13398 class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8247 (Date) Facsimile: (919) 483-7988 Signature of Person Mailing Correspondence CC: Typed or Printed Name of Person Mailing Correspondence P11I ARGE/REV10